Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot study of Abraxane (albumin-bound paclitaxel) and Temodar (temozolomide) plus Genasense (oblimersen sodium) in subjects with advanced melanoma (The ATG study).

Trial Profile

A pilot study of Abraxane (albumin-bound paclitaxel) and Temodar (temozolomide) plus Genasense (oblimersen sodium) in subjects with advanced melanoma (The ATG study).

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oblimersen (Primary) ; Paclitaxel (Primary) ; Temozolomide (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms ATG
  • Sponsors Genta (CEASED)
  • Most Recent Events

    • 17 May 2011 Results will be presented at ASCO-2011, according to a Genta media release.
    • 27 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Jun 2010 Results were presented at ASCO 2010 (abstract no. 8561), according to an Abraxis BioScience media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top